We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Sep 2021
  • Code : CMI4647
  • Pages :149
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Prothrombin complex concentrate is manufactured through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools after the removal of factor XI and antithrombin. These concentrates are used to treat and prevent bleeding in the case of hemophilia B if a pure factor IX is not present.

An emerging factor driving the prothrombin complex concentrate market growth is rising prevalence of hemophilia B

For instance, according to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

The global prothrombin complex concentrates market is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2%  over the forecast period (2021-2028).

Figure 1. Global Prothrombin Complex Concentrates Market Share (%) in Terms of Value, By Region, 2021

PROTHROMBIN COMPLEX CONCENTRATES MARKET

Increasing approval of product by regulatory bodies is expected to increase the growth of the global prothrombin complex concentrates market over the forecast period.

For instance, in 2013, CSL Behring has received the U.S. Food and Drug Administration (FDA) approval for Kcentra (Prothrombin Complex Concentrate) for the indication of  urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure.

Prothrombin Complex Concentrates Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 771.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 10.2% 2028 Value Projection: US$ 1,522.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: 3-Factor PCC, 4-Factor PCC
  • By Application: Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, Others
  • By End User: Hospital, Ambulatory Surgical Centres, Others
Companies covered:

Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin

Growth Drivers:
  • Increasing approval of product by regulatory bodies
  • Increasing prevalence of hemophilia B
Restraints & Challenges:
  • Thrombotic complication related to PCC

Figure 2. Global Prothrombin Complex Concentrates Market Share (%), by Type, 2021

PROTHROMBIN COMPLEX CONCENTRATES MARKET

Global Prothrombin Complex Concentrates Market Restraint

The major factors that hinder the growth of the prothrombin complex concentrates market include thrombotic complication resulting from the use of prothrombin complex concentrates  such as venous thromboembolism, micro vascular thrombosis, and myocardial infraction.

Key Players

Major players operating in the global prothrombin complex concentrates market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc., and Sanquin

Frequently Asked Questions

The global prothrombin complex concentrates market size is estimated to be valued at US$ 771.2 million in 2021 and is expected to exhibit a CAGR of 10.2% between 2021 and 2028.

Increasing approval of products and increasing prevalence of hemophilia B are expected to drive the market growth over the forecast period.

North America holds the largest market share in the market.

Major factor hampering the growth of the market includes the thrombotic complication related to PCC .

Major players operating in the market include Octapharma AG, Nihon Pharmaceutical Co. Ltd., Grifols S.A., CSL Behring GmbH, Kedrion Biopharma Inc., Shire Plc, China Biologic Products Holdings, Inc. and Sanquin

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo